Eli Lilly and Company · LLY
equityHealthcare
Last updated: February 26, 2026
Capital has been gradually leaving Eli Lilly and Company. The Flow & Accumulation Score sits at 40/100, with Chaikin Money Flow at -0.21 indicating net selling pressure over the past 20 trading days. The trend picture is neutral — the Trend & Momentum Score sits at 41/100, suggesting no clear directional conviction. The Risk Profile Score sits at 58/100, reflecting a mediocre return-to-risk balance.
Get this analysis for every asset in your portfolio → Create free account
Where is money flowing?
VWAP: Above 200d ($850.14), below 50d ($1,052.48)
Capital is leaving Eli Lilly and Company. The Flow & Accumulation Score reads 40/100, indicating distribution — selling pressure is outweighing buying pressure over the measurement period. Chaikin Money Flow at -0.21 and On-Balance Volume (flat) provide a mixed picture of flow dynamics.
What is the trend?
| MA Period | Value | Price vs MA | Distance |
|---|---|---|---|
| 10-day | 1,031.75 | Below | -0.9% |
| 21-day | 1,033.44 | Below | -1.1% |
| 50-day | 1,051.85 | Below | -2.8% |
| 100-day | 992.04 | Above | +3.0% |
| 200-day | 870.26 | Above | +17.4% |
Eli Lilly and Company is in a neutral or transitioning phase. The Trend & Momentum Score sits at 41/100, with mixed moving average alignment — no clear trend signal is present. Price has dipped below the 50-day average (-2.8%) while remaining above the 200-day (17.4%) — a pullback within a still-intact long-term uptrend.
Is momentum building or fading?
Short-term momentum is picking up against a negative longer-term backdrop. The 10-day rate of change reads 0.8% while the 63-day sits at -4.3% — a potential early signal of a momentum shift. RSI at 47 sits near the midline — momentum is essentially neutral, with neither buyers nor sellers showing clear dominance.
How extended is this move?
Price sits 2.8% below the 50-day moving average — near or slightly below the intermediate trend line (22nd percentile of its historical range). Bollinger Band %B at 0.37 shows price in the lower half of its recent volatility range.
Where are the key levels?
$1,079.51 – $1,142.92
$984.61 – $1,057.23
The strongest support zone is $985 — $1,057, 1% below current price, where 6 independent signals converge — intermediate swing at $994, SMA-100 at $992, SMA-10 at $1,032, SMA-21 at $1,033, and 2 other signals. Resistance sits at $1,080 — $1,143, 9% above — major swing at $1,112, double top at $1,123, major swing at $1,134, and minor swing at $1,088. The volume Point of Control over the past year sits at $756, where the most trading activity occurred — a significant level if price revisits that area.
How does this compare?
How do your holdings compare? Connect your portfolio for a full relative strength overlay → Create free account
What risk am I taking?
The risk-return profile of Eli Lilly and Company is mediocre. The Risk Profile Score sits at 58/100 — the return-to-risk trade-off is unremarkable, suggesting caution with position sizing. The 1-year Sortino Ratio of 0.6 is below average — returns have barely compensated for the downside volatility. The largest drawdown over the past year reached -32.6%. Beta of 0.12 indicates very low correlation to the broader market — Eli Lilly and Company moves largely independently of equity market swings.
Track your risk exposure across your entire portfolio → Upgrade to Pro
Direction Assessment
Confirmed uptrend with capital inflow
Uptrend without volume support
Capital flowing in, trend not yet established
Downtrend with capital outflow
Average. Standard positioning appropriate.
The combined signal is neutral. With trend at 41/100 and flow at 40/100, neither dimension provides a clear directional reading — the asset is in a transitional or range-bound state. The Risk Profile Score at 58/100 sits in unremarkable territory — in a neutral directional environment, the risk metrics become important for sizing decisions.
Conclusion
Eli Lilly and Company is in a transitional phase. The data does not support a strong directional view — indicators are mixed, and the asset could resolve in either direction. No single indicator is at an extreme — the readings are within normal ranges across the framework, which itself is informative. These scores update daily as new data arrives. Flipside does not predict what happens next — it shows what is happening now, grounded in the data.